Acromegaly Program in Pharmaceutical Benefits Scheme (PBS) 012-18051100

This document outlines details of PBS-subsidised pasireotide and pegvisomant for patients with acromegaly.

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Table 1

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial pasireotide - PB181 form pegvisomant - PB225 form	Written Electronic S100: pasireotide pegvisomant	No	OPA	Not specified	Yes- immediate or delayed assessment (delayed if any free text option used)
Continuing	Telephone Electronic S100: pasireotide pegvisomant	No	OPA	Not specified	Yes
Balance of supply	Telephone Electronic S100: pasireotide pegvisomant	No	OPA	Not Specified	Yes

Table 2: this table lists the details of what to check for the delayed assessment and common acronyms.

Delayed assessment due to contraindication and/or intolerance to octreotide or lanreotide.

Service Officers to assess that free text is:	Examples	Outcome
Relevant to the question	Hypersensitivity to any components of the formulation Gastrointestinal adverse reactions	Approve
Random text	Happy Birthday Patient did not want to take Ikasditbn	Reject
Non-descriptive	Toxicity	Reject

Common acronyms

Escalate to a Pharmaceutical Adviser (PA) by phone if unsure of acronym used.

Operational Information